American Journal of Ophthalmology
Volume 150, Issue 5 , Pages 744-751.e2 , November 2010

Pharmacokinetics of Azithromycin and Moxifloxacin in Human Conjunctiva and Aqueous Humor During and After the Approved Dosing Regimens

  • William C. Stewart

      Affiliations

    • PRN Pharmaceutical Research Network, LLC, Charleston, South Carolina
    • ,
  • Christopher S. Crean

      Affiliations

    • Inspire Pharmaceuticals, Inc, Durham, North Carolina
    • ,
  • Richard C. Zink

      Affiliations

    • Inspire Pharmaceuticals, Inc, Durham, North Carolina
    • ,
  • Kurt Brubaker

      Affiliations

    • Inspire Pharmaceuticals, Inc, Durham, North Carolina
    • ,
  • Reza M. Haque

      Affiliations

    • Inspire Pharmaceuticals, Inc, Durham, North Carolina
    • Corresponding Author InformationInquiries to Reza M. Haque, Inspire Pharmaceuticals, Inc, 4222 Emperor Boulevard, Suite 200, Durham, NC 27703
    • ,
  • David G. Hwang

      Affiliations

    • Cornea Service, Department of Ophthalmology, University of California, San Francisco, California

,Accepted 30 May 2010.

References 

  1. Inspire Pharmaceuticals, Inc.. AzaSite. Durham, NC: Inspire Pharmaceuticals, Inc; 2007;[package insert]
  2. Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25(5):433–439
  3. Alcon Laboratories, Inc.. Vigamox. Fort Worth, TX: Alcon Laboratories, Inc; 2003;[package insert]
  4. Abelson M, Protzko E, Shapiro A, Garces-Soldana A, Bowman L. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. Clin Ophthalmol. 2007;1(2):177–182
  5. Hahn GJ, Meeker WQ. Statistical Intervals: A Guide for Practitioners. New York: John Wiley & Sons; 1991;
  6. Peters DH, Friedel HA, McTavish D. Azithromycin (A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy). Drugs. 1992;44(5):750–799
  7. Abelson MB, Heller W, Shapiro AM, et al. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double masked clinical trial. Am J Ophthalmol. 2008;145(6):959–965
  8. Kuehne JJ, Yu AL, Holland GN, et al. Corneal pharmacokinetics of topically applied azithromycin and clarithromycin. Am J Ophthalmol. 2004;138(4):547–553
  9. Dey S, Gunda S, Mitra AK. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J Pharmacol Exp Ther. 2004;311(1):246–255
  10. Gross RH, Holland GN, Elias SJ, Tuz R. Corneal pharmacokinetics of topical clarithromycin. Invest Ophthalmol Vis Sci. 1995;36(5):965–968
  11. Torkildsen G, O'Brien TP. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. Clin Ther. 2008;30(11):2005–2014
  12. Aihara M, Miyanaga M, Minami K, et al. A comparison of fluoroquinolone penetration into human conjunctival tissue. J Ocul Pharmacol Ther. 2008;24(6):587–591
  13. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea. 2005;24(8):955–958
  14. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112(11):1992–1996
  15. McCulley JP, Caudle D, Aronowicz JD, Shine WE. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006;113(6):955–959
  16. Lai WW, Chu KO, Chan KP, et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol. 2007;144(2):315–318
  17. Holland EJ, Lane SS, Kim T, Raizman M, Dunn S. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea. 2008;27(3):314–319
  18. Crokaert F, Hubloux A, Cauchie P. A phase I determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500 mg once daily for 3 days. Clin Drug Investig. 1998;16(2):161–166
  19. Liesegang TJ. Intracameral antibiotics: questions for the United States based on prospective studies. J Cataract Refract Surg. 2008;34(3):505–509
  20. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology. 1991;98(5):639–650
  21. Miño de Kaspar H, Kreutzer TC, Aguirre-Romo I, et al. A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. Am J Ophthalmol. 2008;145(1):136–142

PII: S0002-9394(10)00410-1

doi: 10.1016/j.ajo.2010.05.039

American Journal of Ophthalmology
Volume 150, Issue 5 , Pages 744-751.e2 , November 2010

Article Tools

* Image Usage & Resolution